Tesofensine

Tesofensine is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.

Pharmacology[edit | edit source]

Tesofensine is a triple monoamine reuptake inhibitor that blocks the action of neurotransmitters such as dopamine, norepinephrine, and serotonin. It is known to induce weight loss and reduce food intake, making it a potential candidate for the treatment of obesity.

Clinical trials[edit | edit source]

In clinical trials, tesofensine has shown significant effects on weight loss in obese patients. In phase II clinical trials, the drug produced a significant weight loss in obese patients without any major side effects. However, the drug is still in the development phase and has not yet been approved for use.

Potential side effects[edit | edit source]

Like other drugs in its class, tesofensine can have side effects. These can include nausea, dry mouth, constipation, hard stools, diarrhea, and insomnia. However, these side effects are usually mild and temporary.

See also[edit | edit source]

Tesofensine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.